Fulcrum Therapeutics Inc. Common Stock (FULC)

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

9

Website

www.fulcrumtx.com/

Fundamentals

1-day range

$3.78$3.87

Market cap

$283.06M

P/E (trailing)

—

P/E (forward)

-7.89

EPS (trailing)

$-0.90

Dividend yield

—

Beta

2.63

Avg. volume

2.90M

Forecasts

4 analyst ratings

Fulcrum Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• FULC

  Fulcrum Therapeutics Inc. Common Stock

  $3.85

  ▲ 0.00%
  Market cap $283.06MP/E —
  $2.83$15.74
• BCYC

  Bicycle Therapeutics plc American Depositary Shares

  $4.21

  ▼ 2.77%
  Market cap $270.87MP/E —
  $3.75$9.16
• IMRX

  Immuneering Corporation Class A Common Stock

  $4.99

  ▼ 4.22%
  Market cap $269.79MP/E —
  $3.86$10.08
• IRD

  Opus Genetics Inc. Common Stock

  $3.7

  ▼ 3.90%
  Market cap $300.54MP/E —
  $1.17$5.81
• ORGO

  Organogenesis Holdings Inc. Class A Common Stock

  $1.74

  ▼ 0.00%
  Market cap $301.10MP/E 84.95
  $1.54$7.08
• ELDN

  Eledon Pharmaceuticals Inc. Common Stock

  $3.19

  ▼ 3.92%
  Market cap $264.75MP/E —
  $1.35$4.6
• ALXO

  ALX Oncology Holdings Inc. Common Stock

  $2

  ▼ 2.44%
  Market cap $259.71MP/E —
  $0.96$2.66

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines
  benzinga · 8/17/2026
• Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines
  Benzinga · 8/17/2026
• Fulcrum Therapeutics And Slate Medicines Merge In All-Stock Deal; Combined Company To Operate As Slate Medicines
  Benzinga · 8/17/2026
• Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit
  Yahoo · 8/5/2026
• Fulcrum Therapeutics: Buy It For The Strategic Reset
  SeekingAlpha · 7/31/2026

• TANG KEVIN · July 17, 2026 · Buy

  50.9K @ $3.52
• TANG KEVIN · July 16, 2026 · Buy

  116.7K @ $3.56
• TANG KEVIN · July 15, 2026 · Buy

  107.4K @ $3.56
• TANG KEVIN · July 14, 2026 · Buy

  76.0K @ $3.58
• TANG KEVIN · July 14, 2026 · Buy

  53.7K @ $3.56
• TANG KEVIN · July 13, 2026 · Buy

  13.0K @ $3.54
• Banks Sonja · June 30, 2026 · Grant

  32.0K
• Alan Ezekowitz · June 30, 2026 · Grant

  32.0K
• Hill Colin · June 30, 2026 · Grant

  32.0K
• Haviland Kate · June 30, 2026 · Grant

  32.0K
• Dorton Katina · June 30, 2026 · Grant

  32.0K
• King Rachel K. · June 30, 2026 · Grant

  32.0K
• Robert J. Gould · June 30, 2026 · Grant

  32.0K
• GERAGHTY JAMES A · June 30, 2026 · Grant

  32.0K
• Lehrer-Graiwer Joshua · April 23, 2026 · Grant

  64.0K

Institutional Ownership

March 31, 2026

Total shares held

71.41M

Total value held

$538.04M

Institutional holders

163